Please ensure Javascript is enabled for purposes of website accessibility

Why Kindred Biosciences Stock Skyrocketed Today

By Joe Tenebruso – Jun 16, 2021 at 4:20PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The pet therapeutics pioneer is being scooped up by a global animal health leader.

What happened

Shares of Kindred Biosciences (KIN) soared 46% on Wednesday after the pet-focused biotech company said it agreed to be acquired by Elanco Animal Health (ELAN 1.03%)

So what

The deal values KindredBio at roughly $440 million, or $9.25 per share. That's a premium of nearly 46% from the stock's closing price on Tuesday.

KindredBio will help to bolster Elanco's pet therapeutic pipeline in fast-growing markets such as dermatology. The combination is also projected to strengthen Elanco's relationships with veterinary clinics. In all, Elanco's management sees the deal boosting the animal health leader's revenue by as much as $100 million by 2025, while also improving its profit margins over time.

A veterinarian is examining a dog.

Image source: Getty Images.

The transaction is expected to close in the third quarter, subject to shareholder and regulatory approval.

"From the beginning, we have been focused at KindredBio on bringing the best medicines to our animal family members," KindredBio co-founder and CEO Richard Chin said in a press release. "With this transaction with Elanco, a widely respected leader in veterinary medicine with global reach, we will maximize the impact our innovative pipeline will have on improving the lives of pets."

Now what

The pet care market has surged during the coronavirus pandemic, as lockdowns and social distancing measures have driven more people to adopt dogs and cats. Americans, in turn, spent a whopping $99 billion on their pets last year, according to The American Pet Products Association. Elanco's leadership knows this, and it's acting aggressively to advance the company's position within this booming market.

"Ultimately, we believe the combination positions Elanco to bring innovative solutions to veterinarians and pet owners in areas of unmet or under-served medical needs, fueling continued growth in the exciting pet therapeutic category and creating sustainable long-term value for shareholders," Elanco CEO Jeff Simmons said.

Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Kindred Biosciences, Inc. Stock Quote
Kindred Biosciences, Inc.
Elanco Animal Health Incorporated Stock Quote
Elanco Animal Health Incorporated
$12.79 (1.03%) $0.13

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.